Posted by Michael Wonder on 07 Dec 2025
FDA approves Omisirge as first approved cell therapy to treat severe aplastic anaemia
5 December 2025 - Ayrmid announces that it has received US FDA approval for Omisirge (Omidubicel-onlv) for the treatment of severe aplastic anaemia.
This approval is based on the on-going open-label, single-center study, led by Dr. Richard Childs of the National Heart, Lung, and Blood Institute at the National Institutes of Health.
